EGFR and non-small cell lung carcinoma: Recent evidence has indicated that β1 integrin expression negatively correlates with sensitivity to the EGFR TKI gefitinib in NSCLC cell lines, as β1 integrin depletion increased sensitivity to gefitinib resulting from enhanced inhibition of EGFR-induced phosphorylation of ERK and Akt [28].